Protocol Ledger

NCT07355218 · Phase III · RECRUITING

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Interventional Phase III clinical trial protocol NCT07355218 sponsored by EMD Serono / Merck KGaA in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-01 Enrollment: 202 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07355218
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)202 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07355218
Protocol FieldVerified Registry Value
NCT IdentifierNCT07355218
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment202 participants (ESTIMATED)
Registered Start Date2026-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07355218
Hospital Research SiteLocationSite Profile
Dawes Fretzin Clinical Research Group, LLCIndianapolis, INOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI